DeutschNewstral
Article
Mmarketwatch.com on 2021-02-03 19:26
Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits
Related news
- MMarijuana-derived epilepsy-drug sales rise 25%, but GW Pharma stock plunges more than 12%marketwatch.com
- MGW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patientsmarketwatch.com
Cannabis Drug Succeeds in Epilepsy, Doubling Value of GW Pharmainfowars.com- MGW Pharma initiated at Leerink with 'outperform' ratingmarketwatch.com
Jazz Pharmaceuticals to Buy GW Pharma for $6.7 Billionwsj.com- LBenefits outweigh risk of legal weedlavozdeanza.com
- MCannabis stocks weighed down by broader market, but Aleafia and GW Pharma shinemarketwatch.com
- MMarijuana stocks to watch: GW Pharma is a drugmaker that grows its own cannabis plantsmarketwatch.com
- MGW Pharma stock jumps to record after DEA stance on its CBD drug, cannabis sector lagsmarketwatch.com
- MGW Pharma stock rallies in declining cannabis sector after strong Epidiolex launchmarketwatch.com
- MGW Pharma shares soar 9% premarket as Oppenheimer upgrades to outperformmarketwatch.com
- MGW Pharma gets EU approval for cannabis-based drug as treatment for severe childhood epilepsymarketwatch.com
- MGW Pharma submits supplemental NDA for Epidiolex to treat seizures from TSCmarketwatch.com
- MGW Pharma shares surge on FDA briefing document that hints at approval of cannabis-derived drugmarketwatch.com
GWPH Stock Forecast: FDA Can Change the Fate for GW Pharma—and Marijuana Stocks?profitconfidential.com- MOPpenheimer lowers GW Pharma price target, tweaks revenue forecasts for Epidiolexmarketwatch.com
- MGW Pharma announces sale of priority review voucher for $105 millionmarketwatch.com
- MGW Pharma shares slide 12% after company swings to loss during pandemicmarketwatch.com
- MMarijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaringmarketwatch.com
- MGW Pharma shares rise after UK recommends NHS reimburse its CBD-based epilepsy drugmarketwatch.com